Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
EMB vs IBB: how they differ
EMB and IBB hold 0% of their weight in the same names, and IBB returned more over the year.
iShares J.P. Morgan USD Emerging Markets Bond ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, EMB and IBB hold 0% of their money in the same securities at the same weight.
| Only in EMB | Only in IBB |
|---|---|
| Argentina Republic Government Internatio 1.12% | Vertex Pharmaceuticals, Inc. 8.09% |
| Argentina Republic Government Internatio 0.73% | Amgen, Inc. 7.84% |
| Argentina Republic Government Internatio 0.64% | Gilead Sciences, Inc. 6.85% |
| Argentina Republic Government Internatio 0.53% | Regeneron Pharmaceuticals, Inc. 4.91% |
| Uruguay Government International Bonds 0.52% | Argenx SE 3.76% |
| EAGLE FUNDING LUXCO SARL 0.51% | Alnylam Pharmaceuticals, Inc. 3.12% |
| Republic of Poland Government Internatio 0.40% | Natera, Inc. 2.89% |
| UKRAINE GOVERNMENT 0.38% | Revolution Medicines, Inc. 2.78% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| EMB iShares J.P. Morgan USD Emerging Markets Bond ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | iShares |
| What it is | J.P. Morgan USD Emerging Markets Bond | Biotechnology |
| Total return, 1 year | +2.8% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −14.7 pts | +24.0 pts |
| Expense ratio | 0.39% | 0.44% |
| Holdings | 681 | 248 |
EMB in plain words
EMB is a bond fund tracking the J.P. Morgan USD Emerging Markets Bond. Over the year to Sep 11, 2026 it returned +2.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.39% a year.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, EMB or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, EMB returned +2.8% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, EMB or IBB?
- EMB charges 0.39% a year and IBB charges 0.44%, so EMB is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, EMB against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/EMB-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources